NCT03291756

CorEvitas Multiple Sclerosis (MS) Registry

Enrolling by Invitation
Not specifiedAges 18+Observational
CorEvitas
~1,000 participants
Updated 2026-02-09 on ClinicalTrials.gov

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of patients with adverse events (AEs) or serious adverse events (SAEs).
Measured over Time Frame: A minimum of 10 years from last patient enrolled
Multiple Sclerosis
1 sites across 1 states
Massachusetts1

This trial hasn't published a contact. View it on ClinicalTrials.gov

  • Number of patients with adverse events (AEs) or serious adverse events (SAEs).Time Frame: A minimum of 10 years from last patient enrolled

    Targeted events include malignancy, anaphylaxis, cardiovascular disease, serious infection, autoimmune disease, MS Relapse, hepatic events, and general serious adverse events. An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.